Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Study on the Safety and Efficacy of BCMA/CD19 Allogeneic CAR-T Cell Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCT

NCT07114432 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT07114432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07114432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Study on the Safety and Efficacy of BCMA/CD19 Allogeneic CAR-T Cell Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCT
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 31, 2025
Completion date
August 31, 2028
Enrollment
19 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed high-risk cytogenetic multiple myeloma patients ineligible or unwilling to undergo asct, newly diagnosed multiple myeloma (ndmm)